Literature DB >> 25439771

One-year results of thoracic endovascular aortic repair for blunt thoracic aortic injury (RESCUE trial).

Ali Khoynezhad1, Carlos E Donayre2, Ali Azizzadeh3, Rodney White2.   

Abstract

OBJECTIVE: One-year outcomes of the RESCUE trial (endovascular aortic repair using Valiant Captivia for blunt thoracic aortic injury) are reported.
METHODS: RESCUE is a prospective, nonrandomized, multicenter trial. Fifty patients with blunt thoracic aortic injury were enrolled between April 2010 and January 2012. One-year outcomes included secondary procedures, device-, procedure-, and/or aorta-related adverse events, and all-cause mortality.
RESULTS: Mean patient age was 40.7 ± 17.4 years; 76% of patients were male. Fifty-two thoracic stent grafts were implanted within a median of 1 day of injury. Seventy percent (35 of 50) of aortic injuries were grade III or higher, including 1 free rupture. The mean Injury Severity Score was 37.6 ± 14.3. Vascular access, device delivery, and deployment were successful in all patients. The left subclavian artery was completely covered in 40% (20 of 50) and partially covered in 18% of patients (9 of 50). There were no strokes or spinal cord injuries. Median procedure time was 90.5 minutes; median hospital stay was 11 days. All-cause mortality within 1 year was 12%. There were no conversions to open repair. Four patients (8%) had subclavian artery revascularization; 1 preoperatively; 3 others postoperatively on days 8, 36, and 103. There were no device-related adverse events. During follow-up, 1 patient (2%) had aortic-related and 9 patients (18%) had procedure-related adverse events.
CONCLUSIONS: TEVAR has favorable early midterm outcomes in the treatment of blunt thoracic aortic injury, and remains the treatment modality of choice. Longevity of the stent grafts in this young patient population has yet to be established.
Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25439771     DOI: 10.1016/j.jtcvs.2014.09.026

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

Review 1.  Endovascular Repair in Acute Complicated Type B Aortic Dissection: 3-Year Results from the Valiant US Investigational Device Exemption Study.

Authors:  Chang Young Lim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-06-05

Review 2.  Blunt thoracic aortic injury - concepts and management.

Authors:  Nicolas J Mouawad; Joseph Paulisin; Stephen Hofmeister; Matthew B Thomas
Journal:  J Cardiothorac Surg       Date:  2020-04-19       Impact factor: 1.637

3.  Thoracic Endovascular Aortic Repair Adverse Events Reported In The Food And Drug Administration Manufacturer And User Facility Device Experience Database.

Authors:  Neel A Mansukhani; Meraaj S Haleem; Mark K Eskandari
Journal:  Med Devices (Auckl)       Date:  2019-11-14

4.  Late Stent Thrombosis in a Patient with Endovascular Aortic Repair for Blunt Thoracic Aortic Injury.

Authors:  Michael H Chiu; Youri Kaitoukov; Amanda Roze des Ordons
Journal:  Case Rep Vasc Med       Date:  2022-02-14

5.  Clinical outcomes of endovascular treatment for ruptured thoracic aortic disease.

Authors:  Jong Hyun Choi; Sang-Pil Kim; Han Cheol Lee; Tae Sik Park; Jong Ha Park; Bo Won Kim; Jinhee Ahn; Jin Sup Park; Hye Won Lee; Jun-Hyok Oh; Jung Hyun Choi; Kwang Soo Cha; Taek Jong Hong
Journal:  Korean J Intern Med       Date:  2020-04-10       Impact factor: 2.884

6.  Endovascular treatment of traumatic dissection of the thoracic aorta - series of 16 cases.

Authors:  Lucas Mansano Sarquis; Wilson Michaelis; Antonio Lacerda Santos; Cristiano Silva Pinto; Rogerio Akira Yokoyama; Erick Fernando Seguro; Antonio Luiz da Costa Martins; Vinicius Belas do Vale
Journal:  J Vasc Bras       Date:  2020-11-16

Review 7.  [Diagnostics and treatment of traumatic aortic injuries].

Authors:  R M Benz; V Makaloski; M Brönnimann; N Mertineit; H von Tengg-Kobligk
Journal:  Unfallchirurg       Date:  2021-07-12       Impact factor: 1.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.